Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A diagnosis of allergic asthma , uncontrolled on current medication.
History of at least 1 asthma exacerbation during the last 1 year
Forced Expiratory Volume in one second (FEV1) of ≥ 40% and ≤ 80% of the predicted normal value; reversibility following administration of bronchodilator must also be demonstrated (historical positive reversibility or bronchoprovocation result can be used).
You may not be if
Baseline IgE levels or body weight outside the omalizumab dosing table.
Use of tobacco products within the previous 6 months (Social occasional smokers may be included).
Recent asthma attack/exacerbation or asthma worsening/ respiratory infection.
Clareo Health | Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
